Who Paid My Doc
Kevin Swiatek
Critical Care Medicine Grand Rapids, MI Doctor of Osteopathy
NPI 1982022901 CMS profile 1401849
4100 Lake Dr Se, Ste 200, Grand Rapids, MI 49546
General payments
$1,679
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kevin Swiatek of Grand Rapids, MI is reported in the CMS Open Payments database as having received $1,679 across 66 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 72nd percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $612 | 21 | |
| 2024 | General | $236 | 12 | |
| 2023 | General | $381 | 15 | |
| 2022 | General | $374 | 17 | |
| 2019 | General | $75 | 1 |
Beside peers
- Kevin Swiatek
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Kevin Swiatek were reported at $612. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Kevin Swiatek | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $75 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $0 | $125 | $34–$403 | $132 |
| 2022 | $374 | $157 | $49–$582 | $149 |
| 2023 | $381 | $162 | $56–$621 | $160 |
| 2024 | $236 | $168 | $53–$634 | $164 |
| 2025 | $612 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 34 drugsPart D claims
1,602
Drug cost
$2,094,706
Branded share of claims
58%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trikafta Elexacaftor/Tezacaftor/Ivacaft | Brand | 31 | $917,669 | |
| Kalydeco Ivacaftor | Brand | 11 | $290,838 | |
| Ofev Nintedanib Esylate | Brand | 19 | $236,464 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 223 | $229,894 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 75 | $80,872 | |
| Pertzye Lipase/Protease/Amylase | Brand | 11 | $61,547 | |
| Creon Lipase/Protease/Amylase | Brand | 20 | $58,065 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 59 | $46,416 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 35 | $28,991 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 61 | $23,384 |
The 10 drugs with the highest cost, of 34 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$39,765
Medicare patients
185
Services billed
465
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 64% | |
| Arthritis | 50% | |
| Ischemic heart disease | 44% | |
| Atrial fibrillation | 42% | |
| Diabetes | 41% | |
| Heart failure | 41% | |
| Depression | 36% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 8 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| YUPELRI |
|
$57 | — | — |
| GLASSIA |
|
$40 | — | — |
| OFEV |
|
$36 | 19 | — |
| BREZTRI |
|
$19 | 75 | — |
| TRELEGY ELLIPTA |
|
$18 | 223 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 8 in the dashboard with a free accountRecords
66 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Michigan
Angel Peralta-Avila
Critical Care Medicine · Detroit, MI
Mujahed Abbas
Critical Care Medicine · Lansing, MI
Abdulrazak Alchakaki
Critical Care Medicine · Southfield, MI
Narayana Gandham
Critical Care Medicine · Saint Joseph, MI
Sara Mirza
Critical Care Medicine · Ann Arbor, MI
Asker Asmi
Critical Care Medicine · Riverview, MI
Related records
Critical Care Medicine in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.